News - Rituxan, Markets & Marketing

Filter

Popular Filters

Biocad enters deal for exporting rituximab biosimilar to Turkey

22-08-2013

Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Global orphan drugs market led by Roche's rituximab

26-02-2013

The global orphan drugs market is estimated to have increased at a compound annual growth rate (CAGR)…

BiotechnologyLucentisMarkets & MarketingNovartisPharmaceuticalRare diseasesRituxanRoche

US rheumatologists continue to increase use of biologics for RA treatment

29-03-2012

Biologic agents remain the preferred treatment for patients suffering from rheumatoid arthritis (RA),…

ActemraAnti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingNorth AmericaOrenciaPharmaceuticalRituxantofacitinib

Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab

01-09-2011

Germany’s Stada Arzneimittel (SAZ: GR) and Hungarian group Gedeon Richter (BDP: RICHTER) have signed…

BiotechnologyGedeon RichterGenericsHerceptinLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRocheSTADA Arzneimitteltrastuzumab

Back to top